Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.49040
Abstract: Key Points Question Does targeting programmed cell death 1 or programmed cell death ligand 1 enhance the clinical benefits of anti–vascular endothelial growth factor therapy in patients with refractory metastatic colorectal cancer (mCRC)? Findings In… read more here.
Keywords: programmed cell; capecitabine bevacizumab; cell death; capecitabine ... See more keywords
Cetuximab plus irinotecan versus panitumumab in patients with refractory metastatic colorectal cancer in Ontario, Canada
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Cancer"
DOI: 10.1002/ijc.30637
Abstract: The addition of irinotecan to an epidermal growth factor receptor (EGFR) antibody has previously been shown to improve tumor response rate and time to progression but not overall survival (OS) for refractory metastatic colorectal cancer… read more here.
Keywords: metastatic colorectal; colorectal cancer; cetuximab plus; ontario canada ... See more keywords
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2024 at "Investigational New Drugs"
DOI: 10.1007/s10637-024-01489-1
Abstract: Antiangiogenic drugs may cause vascular normalization and correct hypoxia in tumors, shifting cells to mitochondrial respiration as the primary source of energy. In turn, the addition of an inhibitor of mitochondrial respiration to antiangiogenic therapy… read more here.
Keywords: colorectal cancer; metastatic colorectal; inhibitor 344; inhibitor ... See more keywords
Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Current problems in cancer"
DOI: 10.1016/j.currproblcancer.2021.100793
Abstract: For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival. This study aims to investigate the efficacy and safety of TAS-102 in a real-world population from Victoria,… read more here.
Keywords: metastatic colorectal; treatment; colorectal cancer; refractory metastatic ... See more keywords
Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-94968-x
Abstract: Given the unclear preference criteria for regorafenib in treating refractory metastatic colorectal cancer (mCRC), this study aimed to construct an algorithm in selecting right patients for regorafenib. This was a multicenter retrospective cohort study. Patients… read more here.
Keywords: treating refractory; preference criteria; criteria regorafenib; refractory metastatic ... See more keywords
Abstract CT165: Phase II open label trial of minnelide™ in patients with chemotherapy refractory metastatic pancreatic cancer
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2019-ct165
Abstract: BackgroundTriptolide and its water-soluble prodrug, Minnelide™, have shown promising activity against pancreatic ductal adenocarcinoma (PDAC) in both in vitro and in vivo experiments. Triptolide induces apoptosis in pancreatic cancer cells by different pathways, including caspase-dependent… read more here.
Keywords: trial minnelide; refractory metastatic; cancer; pancreatic cancer ... See more keywords
Abstract 1582: Cabozantinib changes the tumor microenvironment to increase the efficacy of immunotherapy in refractory metastatic pancreatic ductal adenocarcinoma
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-1582
Abstract: Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. Tumors evade immune surveillance by expressing PD-L1 that interacts with the T cell protein PD-1, subsequently inhibiting CD8+ cytotoxic T lymphocyte proliferation and… read more here.
Keywords: visit; ductal adenocarcinoma; cell; refractory metastatic ... See more keywords
Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Discovery"
DOI: 10.1158/2159-8290.cd-22-0966
Abstract: Metastatic relapse after treatment is the leading cause of cancer mortality, and known resistance mechanisms are missing for most treatments administered to patients. To bridge this gap, we analyze a pan-cancer cohort (META-PRISM) of 1,031… read more here.
Keywords: cancer; refractory metastatic; pan cancer; resistance ... See more keywords
Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
Sign Up to like & getrecommendations! Published in 2018 at "BMC Cancer"
DOI: 10.1186/s12885-018-4872-x
Abstract: BackgroundThe combination of gemcitabine and docetaxel (GT) has been demonstrated to be effective against various types of solid tumors, including sarcoma. However, the regimen has not been confirmed in large, well-designed clinical trials in refractory… read more here.
Keywords: gemcitabine docetaxel; metastatic osteosarcoma; combination gemcitabine; refractory metastatic ... See more keywords
Apatinib as a salvage treatment for refractory metastatic colorectal cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.3556
Abstract: 3556Background: Apatinib, an oral VEGFR2 inhibitor, has been approved as third line treatment for metastatic gastric cancer in China. The aim of this study was to evaluate the efficacy and safety o... read more here.
Keywords: salvage treatment; treatment; treatment refractory; apatinib salvage ... See more keywords
Multiplatform molecular profiling: Observational study to determine the effect of treatment selection in advanced or refractory metastatic solid tumors.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e14730
Abstract: e14730 Background: To assess the clinical benefit of treatment in advanced and refractory solid tumors utilizing evidence-guided molecular profiling (MP) of tumors in routine clinical practice. Methods: This retrospective observational study was conducted on patients… read more here.
Keywords: treatment; refractory metastatic; molecular profiling; solid tumors ... See more keywords